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Abstract
Background: In 2004, universal childhood varicella vaccination was introduced in Germany. We aimed to determine
the age-specific prevalence of anti-varicella zoster virus (VZV) IgG-antibodies among children in the pre-varicella
vaccine era in Germany, to identify factors associated with VZV seropositivity, and to assess the suitability of a
commercially available ELISA for VZV seroepidemiological studies by comparing it with an in-house fluorescent
antibody to membrane antigen test (FAMA) as the gold standard.
Methods: Serum samples of 13,433 children and adolescents aged 1–17 years included in the population-based
German Health Interview and Examination Survey for Children and Adolescents (KiGGS; conducted 2003–2006)
were tested for anti-VZV IgG by ELISA. All samples with equivocal ELISA results and a random selection of ELISA-
negative and -positive samples were tested by FAMA. Statistical analyses were conducted using a weighting factor
adjusting the study population to the total population in Germany. Seroprevalences were calculated as percentages
(%) with a 95% confidence interval (CI). Odds ratios (OR) were computed by multivariate logistic regression to
determine the association between socio-demographic factors and VZV seropositivity.
Results: The VZV seropositivity rate was 80.3% (95% CI: 79.3–81.3) in varicella-unvaccinated children and adolescents.
VZV seropositivity rates differed significantly between age groups up to age 6 years, but not by gender. Of 118 retested
serum samples with an equivocal ELISA result, 45.8% were FAMA-positive. The proportion of samples tested as false-
negative in by ELISA varied by age group: 2.6% in children aged 1–6 and 9% in children aged 7–17 years.
Multivariate analyses showed that age, having older siblings, and early daycare start were associated with seropositivity
in preschoolers; migration background reduced the chance of VZV seropositivity in schoolchildren (OR: 0.65; 0.43–0.99)
and adolescents (OR: 0.62; 0.4–0.97).
Conclusion: In the pre-varicella vaccine era, most children in Germany contracted varicella by age six. Schoolchildren
with a migration background and children without siblings have an increased risk of being VZV seronegative and
should be targeted for catch-up vaccination, if they have no history of chickenpox. ELISAs are suitable for use in
population-level serosurveys on VZV, but samples with equivocal ELISA results should be retested by FAMA.
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Background
Varicella-zoster virus (VZV) is a ubiquitous human her-
pesvirus. Primary infection with VZV results in varicella
(chickenpox), which mostly affects children and is
regarded as a generally benign illness [1]. However, vari-
cella can also lead to serious complications resulting in
hospitalization or even death [2]. Particularly in adults or
in immunocompromised patients, varicella can take a
severe course. After primary infection, immunity against
varicella is considered to protect life-long. However, VZV
becomes latent in the dorsal root ganglia; and later in life,
VZV reactivation can cause herpes zoster (shingles).
In 2004, the German Standing Committee on Vaccin-
ation (STIKO) recommended universal varicella vaccin-
ation for children with a single dose to be given at the age
of 11–14 months [3]. In 2009, a two-dose schedule was
endorsed with a second dose at the age of 15–23 months
[4]. In the birth cohorts of 2004 to 2009, varicella vaccin-
ation coverage increased in 24-month-old children from
43% to 87% for the first dose and from 1% to 64% for the
second dose [5]. With the increase in coverage, a signifi-
cant decrease in varicella cases was observed in a nation-
wide physician-based sentinel surveillance system: from
April 2005 to March 2012, an 85% decline in varicella
cases was reported by sentinel physicians. Furthermore,
from April 2005 to March 2009, complications or severe
courses of varicella declined by 81% [6, 7]. Based on senti-
nel and coverage data, vaccine effectiveness was estimated
to be 87% after one vaccine dose and 97% after two
vaccine doses [8].
For the evaluation of the current universal varicella
vaccination strategy, disease burden data before and
after vaccine introduction as well as data on vaccin-
ation uptake are essential [9]. Seroepidemiological data
before and after vaccine introduction serve as an
additional pillar in the evaluation of the vaccination
strategy and can guide recommendations on catch-up
vaccination activities. Although enzyme-linked im-
munosorbent assays (ELISAs) are the most commonly
used test for measuring immunity against VZV (anti-
VZV IgG antibody levels), the fluorescent antibody to
membrane antigen test (FAMA) is considered to be the
“gold standard” assay for determining immunity against
VZV, however, FAMA is more labor-intensive and
time-consuming [10]. Studies directly comparing these
two test methods are rare.
The objectives of this study were: (1) to representa-
tively describe the age-specific prevalence of anti-VZV
IgG antibodies for children and adolescents in Germany
(1–17 years of age) in the pre-varicella vaccine era, (2)
to identify social factors that are associated with the
acquisition of anti-VZV IgG antibodies by naturally
acquired varicella, and (3) to compare the commercially
available standard ELISA versus an in-house FAMA




From May 2003 to May 2006, the Robert Koch Institute
conducted the German Health Interview and Examin-
ation Survey for Children and Adolescents (KiGGS),
which was designed as a population-based, nationally
representative cross-sectional study with 17,641 partici-
pants (8985 boys and 8656 girls). One participant with-
drew the written consent, and thus 17,640 participants
were included in KiGGS. The sampling methods used in
this survey have been described elsewhere [11]. In
addition to interviews with all parents and children
(≥11 years old) on demographics, socialization, and
health topics, the vaccination status of each child was
documented, and a physical examination of each child
was performed. Furthermore, blood and urine samples
were collected in 1- to 17-year-old children. Serum sam-
ples were stored at −20 °C and subsequently tested for
antibodies against various pathogens. The KiGGS survey
was approved by the Federal Office for Data Protection
and by the ethics committee of Charité University Medi-
cine, Berlin, Germany.
Serological testing
In 2012 and 2013, 13,433 serum samples were tested for
anti-VZV IgG by ELISA. Children vaccinated at least
once against varicella were included in the analysis for
the overall seroprevalence, but the analysis was stratified
by vaccination status in order to allow an assessment of
the pre-varicella vaccine era data. In a second step, sam-
ples that presented equivocal anti-VZV IgG results when
tested by ELISA were retested by FAMA. Samples that
presented anti-VZV IgG-negative results in children
≥6 years of age were also retested by FAMA. For chil-
dren <6 years of age, we selected a random subset of
sera to be tested by FAMA since the proportion of chil-
dren who were anti-VZV IgG-negative in this age group
was expected to be much higher. The analysis of the first
1000 serum samples tested by ELISA already indicated
that younger children have a lower antibody prevalence,
which increased to above 80% in children aged 6 years
and older. Furthermore, we also used FAMA to test 197
randomly selected serum samples that had shown a
positive result in standard ELISA testing.
Enzyme-linked immunosorbent assay (ELISA)
The presence of anti-VZV IgG antibodies in each sam-
ple was determined using the EUROIMMUN Anti-VZV
(IgG) ELISA kit and the EUROIMMUN Analyzer I-2P
(Lübeck, Germany). According to the manufacturer’s
information, anti-VZV IgG concentrations of ≥110 IU/l,
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≥ 80 to <110 IU/l, and <80 IU/l were classed as positive,
equivocal, and negative results, respectively [12]. The
ELISA tests were performed by the National Reference
Center Measles, Mumps, Rubella, which is located at the
Robert Koch Institute, Berlin, Germany.
Fluorescent antibody to membrane antigen test (FAMA)
In our study, FAMAs were conducted using an in-house
modification of the standard version described elsewhere
[13]. VZV immunity was determined by measuring the
level of fluorescent anti-human IgG that was bound to
VZV IgG antibodies linked to viral envelope glycopro-
teins on the surface of VZV-infected fibroblasts. Serum
samples with FAMA titers of ≥1:2 were considered as
positive for immunity against VZV; in other words, these
anti-VZV IgG sera levels correlate with protection
against varicella infection. Detailed information on the
in-house FAMA protocol used in this study has been de-
scribed previously by Sauerbrei et al. [14]. The FAMAs
were carried out at the German Consulting Laboratory
for HSV and VZV, Jena University Hospital, Friedrich-
Schiller-University of Jena, Germany.
Statistical analysis
Analyses of epidemiological and laboratory data were
performed using a weighting factor that adjusted the dis-
tribution of the study population from which a blood
sample could be taken, according age group, sex, resi-
dence in the eastern or western part of Germany or in
Berlin, and according nationality to match the
distribution of these characteristics in the total popula-
tion in Germany as of 31 December 2004 [11]. Weighted
seroprevalence data are reported as percentages (%) with
a 95% confidence interval (CI). ELISA data were strati-
fied by age, gender, and varicella vaccination status. Sig-
nificant differences between the gender and age groups
were assumed if the 95% CIs did not overlap. The test
qualities of ELISA and FAMA were compared descrip-
tively on the basis of non-weighted seroprevalence data.
For risk factor analyses, VZV seropositivity functioned as
the dependent variable and was defined as a positive
ELISA result, or as a positive FAMA result in cases
when the ELISA had shown an equivocal result. The
weighted data set was used. Multivariate logistic regres-
sion analyses for complex samples were used to deter-
mine possible factors associated with VZV seropositivity
(inclusion of variables was guided by hypotheses: age,
gender, older and younger siblings living in the same
household, migration status, social economic status
(SES) and age at start of day-care attendance). The social
status score was computed based on three components:
parents’ educational and professional statuses as well as
the total income available to the family household [15].
Analyses were performed with SPSS version 20 (SPSS
Inc., Chicago, Illinios, USA).
Results
Of the 17,640 KiGGS participants, 13,433 children and
adolescents that were 1–17 years of age were included in
the VZV seroprevalence study. Of those excluded from
Fig. 1 Flow chart indicating the total number of children in the study sample (sera collected 2003–2006, N = 17,641) and number of children
eventually tested for anti-VZV IgG antibodies by ELISA
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this study, 935 of the children were <1 year of age and
blood sampling was not performed in this age group,
2318 of the children had no available serum sample, and
954 of the children had a serum samples of insufficient
quantity (Fig. 1). Gender was distributed evenly in the
study population with 6881 (51%) males and 6552 (49%)
females. Each age group (1 to 17 years), had 437 to 938
participants included. The mean age of all study partici-
pants was 10.1 years (median age: 10.3 years). Of the
13,433 children included, 232 (1.7%) had a vaccination
card with at least one vaccination against varicella docu-
mented, while 924 (6.9%) children had no vaccination
card available. In Table 1, the weighted VZV seropreva-
lence data are shown stratified by varicella vaccination
status. Of the 13,433 sera tested by ELISA, 11,091 (esti-
mated weighted overall VZV seroprevalence rate: 80.3%)
samples were classified as positive, 120 (0.9%) samples
presented an equivocal result, and 2222 (18.8%) samples
were found to be negative for anti-VZV IgG (Table 1).
Varicella-vaccinated children and children with no vac-
cination card available were excluded from further ana-
lyses that focused on the seroprevalence and risk of
being varicella susceptible in the varicella-unvaccinated
population. In Table 2, weighted VZV seropositivity rates
detected by ELISA are given for each age group in
varicella-unvaccinated children. While VZV seropositiv-
ity increased with age with significant differences be-
tween single age groups up to the age of 6 years, no
Table 1 Weighted VZV seroprevalence data tested by ELISA and stratified by varicella vaccination status in children 1–17 years of




Varicella vaccination status Total
No vaccination card available Varicella vaccinated Not varicella vaccinated
Positive number (n) 811 124 10,156 11,091
weighted rate (%) 87.7% 48.9% 80.3% 80.3%
95% CI [%] [84.8–90.1] [40.2–57.8] [79.3–81.3] [79.4–81.2]
Negative number (n) 109 90 2023 2222
weighted rate (%) 12.0% 41.4% 18.9% 18.8%
95% CI [%] [9.7–14.8] [34.4–48.8] [18.0–19.9] [17.9–19.8]
Equivocal result number (n) 4 18 98 120
weighted rate (%) 0.3% 9.6% 0.7% 0.9%
95% CI [%] [0.1–1.0] [5.7–15.9] [0.6–0.9] [0.7–1.1]
Total number (n) 924 232 12,277 13,433
weighted rate (%) 100.0% 100.0% 100.0% 100.0%
Table 2 Weighted VZV seroprevalence rates stratified by age in varicella-unvaccinated children 1–17 years of age, Germany
Anti-VZV IgG antibodies tested by ELISA,
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significant difference in VZV seropositivity was detected
between males and females (Fig. 2).
Of the 2222 serum samples that tested negative for
anti-VZV IgG by ELISA, 919 samples of children aged
1–6 years and 535 samples of children aged 7–17 years
were subsequently examined by FAMA. This test found
24 (2.6%) samples in the age group of 1–6 years and 48
(9.0%) samples in the age group of 7–17 years to be
positive. Additionally, 118 of the 120 serum samples that
presented an equivocal result by ELISA were tested by
FAMA. Of these, 54 (45.8%) samples were assessed as
positive by this test. Of the 197 serum samples taht
demonstrated a positive ELISA result, 195 (99%) were
also FAMA-positive, while only 2 (1%) samples were
assessed as negative by FAMA (Fig. 3). In Table 3, we
present stratified ELISA and FAMA results by varicella
Fig. 2 Weighted VZV seropositivity rate stratified by age and sex in varicella-unvaccinated children 1–17 years of age, Germany (sera collected
2003–2006, n = 12,277)
Fig. 3 Flow chart of study subjects for VZV seroprevalence testing by FAMA in children 1–17 years of age, Germany (sera collected
2003–2006, n = 13,433)
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vaccination status. Serum samples from varicella-
vaccinated children that had produced either negative or
equivocal ELISA results were more frequently assessed
as positive by FAMA than were serum samples from
varicella-unvaccinated children.
In a logistic regression for complex samples, we did
not observe any significant association between VZV
seropositivity and either the socioeconomic status or the
sex of the child. In children who were 1–10 years of age,
increasing age was significantly associated with the ac-
quisition of anti-VZV IgG antibodies. In 1- to 6-year-old
children, the presence of older siblings in the same
household was related to a higher probability of VZV
seropositivity, and in children 7–17 years of age, younger
siblings or siblings of the same age functioned as risk
factor for VZV seropositivity. Thus, children without sib-
lings in the same household were more likely to be anti-
VZV IgG-negative and, therefore, susceptible to con-
tracting chickenpox. Children aged 7–17 years whose
parents both had a migration background showed a sig-
nificantly lower likelihood of VZV seropositivity than
children without a migration background or with a one-
sided migration background. The start of day-care
attendance at younger ages was also significantly associ-
ated with VZV seropositivity (Table 4).
Discussion
Here, we report for the first time representative
population-based VZV seroprevalence data for children
aged 1 to 17 years in the pre-varicella vaccine era in
Germany. VZV seropositivity increased with age, with
60% of children testing positive at 4 years of age and
>90% testing positive at 9 years of age. This gradual in-
crease in VZV seropositivity by age is comparable with
the VZV seroprevalence data of German children
<18 years of age that were reported by Wutzler et al. in
2001 [13]. For this earlier seroprevalence study, two
serum banks were used with residual serum samples
that had originally been collected for routine laboratory
diagnostics or within the German National Health
Interview and Examination Survey between 1995 and
1999. They found that VZV seropositivity was 62% in
the 4- to 5-year old children and >90% in the 10- to 11-
year old children. Thus, the seroprevalence data of the
1995–1999 study are similar to ours, and we can as-
sume that there was no significant change in the VZV
seroprevalence in children in Germany for the time
period between 1995 and 1999 and 2003–2006. Also
similar to our results, the majority of varicella infection
occurred in early childhood in Northern European
countries without universal varicella vaccination [16].
Interestingly, children in the Netherlands acquired anti-
VZV IgG antibodies, on average, even earlier in child-
hood than did children in Germany or in Nordic coun-
tries, and some have proposed that the relatively high
population density in the Netherlands might explain this
observation [17]. There are contradicting reports from the
Netherlands concerning whether or not VZV seropositiv-
ity is associated with day-care attendance [17, 18]. In our
study, we found an association between VZV seropositiv-
ity and an early (<3 years of age) start of day care attend-
ance. However, this finding may be explained by the low
rate of young children (0–3 years of age) who attend day
care facilities at all in Germany. In 2006, around 12% of
children who were <3 years of age visited a day care center
in Germany [19]; in contrast, around 50% of children in
the Netherlands who were <3 years of age attended day
care facilities in 2010 [20]. Since we can assume that in
the absence of varicella vaccination the force of varicella
infection was high in day care facilities, we were able to
discriminate in regard to VZV seropositivity between
children with an early start of day care attendance and
children who stayed at home. Additionally, we showed
that siblings living in the same household acted as a risk
factor for acquiring varicella: for young children, older
siblings in the same household were a risk factor for VZV
seropositivity, and, for older children, their younger
Table 3 Results of ELISA and FAMA for the detection of anti-VZV
IgG antibodies in sera of children 1–17 years of age (n = 1769
tested by ELISA and FAMA). The data set was stratified by the
varicella vaccination status of the children. Germany
ELISA positive
FAMA
positive n (%) negative n (%) total n (%)
varicella vaccinated 5 (100%) 0 5 (100%)
not varicella vaccinated 176 (99%) 2 (1%) 178 (100%)
no vaccination card 14 (100%) 0 14 (100%)
total 195 (99%) 2 (1%) 197 (100%)
ELISA negative
FAMA
positive n (%) negative n (%) total n (%)
varicella vaccinated 12 (25.5%) 35 (74.5%) 47 (100%)
not varicella vaccinated 53 (4.0%) 1268 (96.0%) 1321 (100%)
no vaccination card 7 (8.1%) 79 (91.9%) 86 (100%)
total 72 (5.0%) 1382 (95.0%) 1454 (100%)
ELISA equivocal result
FAMA
positive n (%) negative n (%) total n (%)
varicella vaccinated 12 (66.7%) 6 (33.3%) 18 (100%)
not varicella vaccinated 39 (40.6%) 57 (59.4%) 96 (100%)
no vaccination card 3 (75.0%) 1 (25.0%) 4 (100%)
total 54 (45.8%) 64 (54.2%) 118 (100%)
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siblings played this role. Thus, in the absence of universal
varicella vaccination in children, our data confirm that
children are the major force of varicella infection.
There are concerns about an upward shift in vari-
cella infection age following the introduction of uni-
versal varicella vaccination in young children [21].
Our study adds to the efforts of monitoring the im-
pact of varicella vaccination in Germany, in part to
address these concerns. Despite these worries, this
phenomenon has not been observed in varicella sur-
veillance in Germany, which is a physician-based sen-
tinel system established in 2005 shortly after the
initiation of universal childhood varicella vaccination
[22]. Similarly, in the United States, where universal
varicella vaccination in children was implemented in
1995, no shift in varicella cases towards older age
groups has been observed as of today [23]. This
present serosurvey will serve as a baseline assessment,
and a follow-up survey (KiGGS wave 2) which will
allow a comparison between more recent results and
those of this present study, is currently underway and
will recruit children from 2014 to 2017.
In our survey, we detected subgroups within the gen-
eral population that have an increased risk of being sus-
ceptible to varicella infection if they are not reached by
an ad-hoc catch-up vaccination; children 7–17 years of
age with a migration background and children without
siblings were less likely to be anti-VZV IgG-positive.
Since no concerted catch-up campaign has been imple-
mented among older children or adolescents following
the introduction of universal childhood vaccination in
toddlers, pediatricians and general practitioners should
be aware of this fact and provide individual varicella
catch-up vaccinations to these risk groups if an individ-
ual lacks a history of chickenpox and has no docu-
mented varicella vaccination. STIKO recommends
Table 4 Results of the logistic regression model with VZV seropositivity as the dependent variable; data set stratified in three age
groups: children 1 to 6 years of age, 7 to 10, and 11 to 17 years of age. Variables with statistically significant results presented here.
Germany (sera collected 2003–2006, available for logistic regression model n = 11,374)
Age 1 to 6 years Age 7 to 10 years Age 11 to 17 years
n = 3162 n = 3058 n = 5154
Variable OR 95% CI OR 95% CI OR 95% CI
Age 1 year Referent
2 years 2.2 1.4–3.7
3 years 4.1 2.5–6.9
4 years 11.0 6.6–18.3
5 years 21.7 12.8–37.1
6 years 51.0 30.6–85.3
7 years Referent
8 years 1.4 1.0–1.9
9 years 2.0 1.3–3.1
10 years 2.5 1.6–4.1
Siblings living in the same household:
only child Referent Referent Referent Referent Referent Referent
younger or same age of the siblings 1.1 0.9–1.5 1.7 1.1–2.6 1.7 1.2–2.4
older siblings 2.3 1.9–2.9 1.3 0.9–1.8 1.2 0.8–1.8
Age at start of day-care attendance
(1 to 10 year olds)
< 1 year 1.6 1.0–2.5 1.8 0.7–4.2
1 year 1.6 1.1–2.2 2.0 1.1–3.5
2 years 1.3 0.9–1.8 4.1 2.2–7.7
> = 3 years 0.9 0.7–1.2 1.7 1.2–2.4
Migration background:
none 1.3 0.9–1.7 1.5 1.0–2.3 1.6 1.0–2.5
one-sided 1.1 0.7–1.7 1.3 0.6–2.5 1.5 0.8–3.0
two-sided Referent Referent Referent
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individual catch-up vaccination to all children up to
their 18th birthday and to all VZV-seronegative women
of childbearing age.
We compared the detection of anti-VZV IgG by a
commercially available ELISA with that by an in-house
FAMA, which can be regarded as the gold standard
[24]. We observed that 45.8% of samples with equivocal
ELISA results were assessed as positive by FAMA.
Additionally, 2.6% and 9.0%, respectively (depending on
the age of the tested children), of ELISA-negative
serum samples were determined to be positive by
FAMA. As the gold standard assay, FAMA has a higher
sensitivity and a lower detection limit than an ELISA
[25]. The EUROIMMUN Anti-VZV (IgG) ELISA was
reported to have a significantly lower sensitivity than
FAMA, especially for the detection of anti-VZV IgG
after varicella vaccination has been performed [14].
Interestingly, when serum samples that produced a
negative or equivocal ELISA result were tested by
FAMA, we more often observed a positive FAMA re-
sult in samples from varicella-vaccinated children than
in samples from varicella-unvaccinated ones (Table 3).
Although there was only a small number of varicella-
vaccinated children in the study sample, our findings
might be important for the monitoring of VZV sero-
prevalence in a varicella-vaccinated population. Because
it is possible that anti-VZV IgG levels in varicella-
vaccinated populations are overall lower, which would
lead to a higher frequency of equivocal or even negative
ELISA results, retesting these sera by FAMA might
become much more relevant. Unfortunately, FAMA is a
labor-intensive and time-consuming method that is not
amenable to automation and requires experience for an
appropriate interpretation of its results. Currently,
FAMA tests are only performed in laboratories that are
highly specialized in VZV diagnostics and research, and
they are not commercially available. Therefore, it will
be difficult to conduct FAMA for the detection of anti-
VZV IgG on a routine basis.
Our study has several limitations. For the weighted
seroprevalence rate calculation for varicella-unvaccinated
children 1–17 years of age, we excluded 1156 study sub-
jects with at least one reported varicella vaccination or
with no vaccination card presented. Furthermore, most of
the information on migration status, family members, and
SES were self-reported or reported by the parents. How-
ever, this limitation would only influence the results of the
risk factor analysis, not the VZV seroprevalence data.
Conclusion
In our study, we determined the age-specific VZV sero-
prevalence among children and adolescents in the pre-
varicella vaccine era in Germany. We confirmed that, in
the absence of universal varicella vaccination, VZV
seropositivity increased with age, especially in the first
6 years of life, which suggests that the major force of
varicella transmission occurred in young children. We
identified children without siblings in the same house-
hold and children with a migration background as being
more susceptible to contracting varicella, even at higher
ages (7–17 years old). Therefore, varicella-unvaccinated
children or adolescents should be targeted for catch-up
activities if they lack a history of chickenpox.
We also compared the test qualities of a commercially
available ELISA with those of a gold standard test
(FAMA). A high number of serum samples with a nega-
tive or equivocal result in the ELISA produced a positive
FAMA result, especially those from varicella-vaccinated
children. Our findings suggest that the commercially
available ELISA can be used for the monitoring the VZV
seroepidemiology in populations with or without an
established universal varicella vaccination, but that
FAMA testing is superior in situations with equivocal
ELISA results or in ELISA-negative samples from indi-
viduals who were vaccinated against varicella in the past.
This study provides baseline data on VZV seroepide-
miology in children and adolescents for monitoring the
impact of the recently implemented varicella vaccination
strategy in Germany. Moreover, these data act as input
for mathematical modelling of the varicella and herpes
zoster-attributable disease burden and of future epi-
demiological effects of the varicella-vaccination [26].
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